Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Parx Plastics' Antibacterial Polymer Gains EU Patent

Parx Plastics was granted an EU patent application for use of the company’s biocompatible technologies in polymer components of orthopedic implants (e.g. hip and knee joints).

Parx technologies are incorporated in Saniconcentrates™. The plastic receives an intrinsic change on a micrometric scale which results in antiseptic and antibacterial characteristics due to improvements in mechanical and physical properties. Surfaces are more resistant to attack by microbes and bacteria, lessening the risk of biofilm adhesion. 

Saniconcentrates are produced with the aid of zinc, a body's own trace-element. Saniconcentrates do not contain biocides or silver. The technology is entirely intrinsic in the material.

In vivo studies have shown that Parx technologies effectively prevent surface biofilm adhesion. Parx Plastics seeks to partner with a knowledgeable player for co-development of its technology in the orthopedic field. 

Parx represents yet another approach to the pressing problem of post-surgical infection, joining other initiatives in packaging, convening of an International Consensus Meeting on Musculoskeletal Infection and development of various coatings which also address implant loosening.

Source: Parx Plastics